Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenosine Therapeutics
Adenosine in-licenses the rights to technology for use in cardiac, cancer, vaccine applications
October 13th, 2006
Adenosine Therapeutics, LLC announced that it has signed agreements with the University of Massachusetts Medical School (UMMS) and the National Institutes of Health (NIH) to license potentially important technology in the cardiac, cancer and vaccine fields. An exclusive license for the rights to U.S. Patent 5629298, "Adenosine as a Positive Inotrope in the Compromised Heart" has been executed with UMMS. The patent is based on work done by James G. Dobson Jr., PhD, professor of physiology and medicine at UMMS. The terms of the agreement were not revealed. Adenosine Therapeutics has also completed a licensing agreement with the NIH to in-license a...
Source: Medicine & Law Weekly (2006-10-13)
|
